LYZL2
Lysozyme-like protein 2
Also known as: LYZL2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q7Z4W2
- Gene
- LYZL2
- Ensembl
- ENSG00000151033
- Chromosome
- 10
- Canonical length
- 148 aa
- Protein class
- Enzymes, Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted in male reproductive system
OverviewNCBI Gene
Lysozymes (see LYZ; MIM 153450), especially C-type lysozymes, are well-recognized bacteriolytic factors widely distributed in the animal kingdom and play a mainly protective role in host defense. LYZL2 is a member of a family of lysozyme-like genes (Zhang et al., 2005 [PubMed 16014814]).[supplied by OMIM, Apr 2009]
Canonical amino-acid sequenceUniProt
148 residues, UniProt reviewed canonical sequence.
>Q7Z4W2|LYZL2
1 MKAAGILTLI GCLVTGAESK IYTRCKLAKI FSRAGLDNYW GFSLGNWICM AYYESGYNTT
61 AQTVLDDGSI DYGIFQINSF AWCRRGKLKE NNHCHVACSA LVTDDLTDAI ICAKKIVKET
121 QGMNYWQGWK KHCEGRDLSD WKKDCEVSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LYZL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.33
- Highest tissue expression
- 68 nTPM
Expression across tissuesHPA
Tissue
- testis: 68 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
- appendix: 0 nTPM
- basal ganglia: 0 nTPM
Single-cell type
- early spermatids: 784 nCPM
- late primary spermatocytes: 506 nCPM
- late spermatids: 231 nCPM
- cardiomyocytes: 3.3 nCPM
- sertoli cells: 2.8 nCPM
- leydig cells: 1.6 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.79
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.77
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LYZL2 as an antibody target. Whether an autoantibody or antibody against LYZL2 could matter depends on whether native LYZL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LYZL2 is annotated as secreted, so native LYZL2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label LYZL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...